Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $32.3 million.

  • Enanta Pharmaceuticals' Cash & Equivalents fell 1325.44% to $32.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year decrease of 1325.44%. This contributed to the annual value of $32.3 million for FY2025, which is 1325.44% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash & Equivalents stood at $32.3 million for Q3 2025, which was down 1325.44% from $44.8 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash & Equivalents peaked at $99.1 million during Q4 2021, and registered a low of $4.6 million during Q2 2021.
  • Its 5-year average for Cash & Equivalents is $55.0 million, with a median of $44.8 million in 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Cash & Equivalents crashed by 9539.23% in 2021 and then soared by 51653.99% in 2022.
  • Enanta Pharmaceuticals' Cash & Equivalents (Quarter) stood at $99.1 million in 2021, then tumbled by 57.38% to $42.2 million in 2022, then decreased by 5.42% to $39.9 million in 2023, then surged by 111.23% to $84.3 million in 2024, then plummeted by 61.71% to $32.3 million in 2025.
  • Its Cash & Equivalents stands at $32.3 million for Q3 2025, versus $44.8 million for Q2 2025 and $60.2 million for Q1 2025.